177Lu-DOTATATE Shows Promising Efficacy in the Treatment of Patients with Progressive Metastatic Pheochromocytomas and Paragangliomas By Ogkologos - September 2, 2025 233 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the Phase II study Source RELATED ARTICLESMORE FROM AUTHOR Treatment with Encorafenib Plus Cetuximab Plus FOLFIRI Improves Outcomes in Patients with BRAF V600E-mutated mCRC FDA Approves Belzutifan with Pembrolizumab for Adjuvant Treatment of Renal Cell Carcinoma How Decades of NCI Support Led to Groundbreaking Discoveries: The Story of Immune Checkpoint Inhibitors MOST POPULAR Gynaecological Cancers: Immunotherapy and Novel Targeted Drug Appear Beneficial in Group... September 13, 2024 Breaking down changes in NHS cancer waiting times in England August 17, 2023 EMA Recommends Granting a Conditional Marketing Authorisation for Adagrasib Following a Re-Examination... November 17, 2023 Study Advances Fertility Preservation Approach for Male Cancer Survivors April 24, 2019 Load more HOT NEWS FDA Approves First Comprehensive Pan-Tumour Liquid Biopsy Test for Patients with... Protective HPV Vaccine-Induced Antibody Titres Can Be Detected Up To 12... Mosunetuzumab Plus Polatuzumab Vedotin Shows Promise for Patients with Aggressive Relapsed... Potential for Larger Gene Panels to Increase the Number of Molecularly...
